Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib plus gemcitabine in relapsed/refractory peripheral T-cell or NK/T-cell lymphomas
KCT0007893Phase 2Completed
- Sponsor
- Yuhan
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of copanlisib, gemcitabine in peripheral T-cell lymphoma (PTCL), natural killer/T-cell lymphoma (NKTL), sponsored by Yuhan. Started Apr 2019; status: completed.
02
Drugs
copanlisibgemcitabine
03
Conditions
peripheral T-cell lymphoma (PTCL)natural killer/T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on KCT0007893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007893.